UNSPSC 51101907: Pyrimethamine

This classification denotes a dihydrofolate reductase inhibitor and antimalarial agent with the molecular formula C12H13ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z3614QOX8W, chemically known as 2,4-pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl- but generally known as pyrimethamine, which bears US NIH Compound Identifier 4993. European Medicines Agency schedules Pyrimethamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10169MIG.

UNSPSC 51101907 Pyrimethamine is a Commodity code nominally identifying a single antimalarial pharmaceutical product, but the recent state and local solicitations tagged under this code show little activity actually procuring pyrimethamine itself. Instead, the opportunities reflect state and local health agencies and public safety organizations buying a broader range of pharmaceuticals, medical supplies, and pharmacy services. The City of Tampa's Fire Department is procuring 169 line items of medical and first aid supplies through an IFB, including respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, and oxygen delivery systems; Seminole County, Florida issued an IFB for naloxone and drug deactivation systems; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers; and the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs. Issuing bodies span state health departments, county health systems, municipal fire departments, and cooperative purchasing vehicles serving multiple jurisdictions. The code shows significant mismatch between its nominal scope and the actual work being solicited under it.

Geographic activity concentrates in Florida, Minnesota, Texas, and Oregon, with the MMCAP cooperative purchasing vehicle serving multiple states. Representative recent opportunities include the City of Tampa's March 2026 IFB for medical and first aid supplies (response due March 13, 2026, estimated contract value $700,000 with a 5 percent bid discount available to certified Small Local Business Enterprises), Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with quarterly deliveries (due July 26, 2023), and MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products (due March 26, 2026, with contract effectiveness July 1, 2026). The Texas HHS RFI posted April 3, 2026 represents exploratory procurement rather than a binding solicitation, gathering vendor capabilities for future direct-to-manufacturer pharmacy contracting. The code's low relevance to actual procurement activity suggests limited opportunity for vendors specializing in pyrimethamine specifically, though broader pharmaceutical and medical supply firms may find relevant openings in the health department and municipal emergency response contracts listed here.